Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics (NTLA) on Tuesday, extending a recent buying trend in the stock. The firm’s continued buying suggests it remains confident in the company’s longer-term prospects, even as biotech stocks remain volatile.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In its latest trade update for January 13, 2026, ARK bought 40,067 shares of Intellia. Most of the shares were added through the ARK Innovation ETF (ARKK), with a smaller portion purchased via the ARK Genomic Revolution ETF (ARKG). The total value of the buy was about $458,000.
(Note: To see more of Cathie Wood’s January 9 trades, click here — NTLA, PSNL, KMTUY, ILMN: Cathie Wood Buys Early Biotech Stocks, Cuts Stakes in Illumina.)
This was not a one-time move. A day earlier, ARK added 99,292 shares of Intellia, and earlier last week, it bought 216,411 shares. While Tuesday’s trade was smaller, the steady buying shows ARK is still adding to the position.
The recent buying comes ahead of a potential catalyst. Intellia is set to present at the J.P. Morgan Healthcare Conference on January 14, a forum where biotech companies often provide updates on their pipelines and plans. Investors will be watching closely for any updates on Intellia’s CRISPR programs and next steps.
Is Intellia a Good Stock to Buy?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on Intellia stock based on nine Buys, 12 Holds, and one Sell assigned in the past three months. At $16.50, the average NTLA stock price target implies a 40.55% upside potential. Year-to-date, shares of the company have gained 30.6%.
